246 related articles for article (PubMed ID: 26100858)
21. Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.
Song G; Tarrant TK; White TF; Barrow DA; Santos CM; Timoshchenko RG; Hanna SK; Ramanathan RK; Lee CR; Bae-Jump VL; Gehrig PA; Zamboni WC
Nanomedicine; 2015 Oct; 11(7):1797-807. PubMed ID: 26093057
[TBL] [Abstract][Full Text] [Related]
22. A comparison of overall survival with 40 and 50mg/m
Nakayama M; Kobayashi H; Takahara T; Nishimura Y; Fukushima K; Yoshizawa K
Gynecol Oncol; 2016 Nov; 143(2):246-251. PubMed ID: 27612976
[TBL] [Abstract][Full Text] [Related]
23. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
Giovinazzo H; Kumar P; Sheikh A; Brooks KM; Ivanovic M; Walsh M; Caron WP; Kowalsky RJ; Song G; Whitlow A; Clarke-Pearson DL; Brewster WR; Van Le L; Zamboni BA; Bae-Jump V; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):565-73. PubMed ID: 26822231
[TBL] [Abstract][Full Text] [Related]
24. Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.
Betof AS; Rabbani ZN; Hardee ME; Kim SJ; Broadwater G; Bentley RC; Snyder SA; Vujaskovic Z; Oosterwijk E; Harris LN; Horton JK; Dewhirst MW; Blackwell KL
Br J Cancer; 2012 Feb; 106(5):916-22. PubMed ID: 22333602
[TBL] [Abstract][Full Text] [Related]
25. Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment.
Tanguay JS; Ansari J; Buckley L; Fernando I
Int J Gynecol Cancer; 2009 Apr; 19(3):361-6. PubMed ID: 19407560
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
[TBL] [Abstract][Full Text] [Related]
27. Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
Herzog TJ; Kutarska E; Bidzińsk M; Symanowski J; Nguyen B; Rangwala RA; Naumann RW
Int J Gynecol Cancer; 2016 Nov; 26(9):1580-1585. PubMed ID: 27654255
[TBL] [Abstract][Full Text] [Related]
28. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA
J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448
[TBL] [Abstract][Full Text] [Related]
29. The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial.
Miyahara D; Ueda T; Katsuda T; Maehara M; Fukagawa S; Miyata K; Nam SO; Kondo H; Miyamoto S
Anticancer Res; 2015 Aug; 35(8):4521-5. PubMed ID: 26168496
[TBL] [Abstract][Full Text] [Related]
30. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
[TBL] [Abstract][Full Text] [Related]
31. [Safety of PLD in the treatment of the patients with recurrent ovarian cancer--clinical experience].
Malkowska-Walczak B; Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2009 Sep; 80(9):682-6. PubMed ID: 19886242
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment.
Morotti M; Valenzano Menada M; Venturini PL; Ferrero S
Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):707-20. PubMed ID: 21434836
[TBL] [Abstract][Full Text] [Related]
33. Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.
Nygård SB; Christensen IJ; Smith DH; Nielsen SL; Jensen NF; Nielsen HJ; Vainer B; Brünner N
Scand J Gastroenterol; 2013 Dec; 48(12):1436-43. PubMed ID: 24138107
[TBL] [Abstract][Full Text] [Related]
34. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays.
Ju W; Yoo BC; Kim IJ; Kim JW; Kim SC; Lee HP
Oncol Res; 2009; 18(2-3):47-56. PubMed ID: 20066894
[TBL] [Abstract][Full Text] [Related]
35. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
36. Translational control of TOP2A influences doxorubicin efficacy.
Srikantan S; Abdelmohsen K; Lee EK; Tominaga K; Subaran SS; Kuwano Y; Kulshrestha R; Panchakshari R; Kim HH; Yang X; Martindale JL; Marasa BS; Kim MM; Wersto RP; Indig FE; Chowdhury D; Gorospe M
Mol Cell Biol; 2011 Sep; 31(18):3790-801. PubMed ID: 21768308
[TBL] [Abstract][Full Text] [Related]
37. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer.
Adams SF; Marsh EB; Elmasri W; Halberstadt S; Vandecker S; Sammel MD; Bradbury AR; Daly M; Karlan B; Rubin SC
Gynecol Oncol; 2011 Dec; 123(3):486-91. PubMed ID: 21945552
[TBL] [Abstract][Full Text] [Related]
38. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
39. A study of pegylated liposomal Doxorubicin in platinum-refractory epithelial ovarian cancer.
Wilailak S; Linasmita V
Oncology; 2004; 67(3-4):183-6. PubMed ID: 15557776
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
